Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
---|---|---|---|---|---|---|---|
ENANTA PHARMACEUTICALS INC | Chief Legal Officer | Stock Option (right to buy) | 150K | Apr 29, 2024 | Direct | ||
Sigilon Therapeutics, Inc. | CHIEF OF STAFF AND CLO | Common Stock | 0 | Aug 11, 2023 | Direct | ||
Sigilon Therapeutics, Inc. | CHIEF OF STAFF AND CLO | Stock Option (Right to Buy) | 0 | $0.75 | Aug 11, 2023 | Direct |
Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
---|---|---|---|---|---|---|---|
ENTA | ENANTA PHARMACEUTICALS INC | Apr 29, 2024 | 1 | $0 | 4 | May 1, 2024 | Chief Legal Officer |
ENTA | ENANTA PHARMACEUTICALS INC | Apr 29, 2024 | 0 | $0 | 3 | May 1, 2024 | Chief Legal Officer |
SGTX | Sigilon Therapeutics, Inc. | Aug 11, 2023 | 2 | -$9.52K | 4 | Aug 11, 2023 | CHIEF OF STAFF AND CLO |
SGTX | Sigilon Therapeutics, Inc. | Feb 28, 2023 | 1 | $0 | 4 | Mar 1, 2023 | CHIEF OF STAFF AND CLO |
SGTX | Sigilon Therapeutics, Inc. | Feb 28, 2023 | 0 | $0 | 3 | Mar 1, 2023 | CHIEF OF STAFF AND CLO |